Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Healthcare momentum candidate with shareholder support: stock rose about 23% over 21 trading days and is near recent highs. Q1 2026 revenue was $328.5M with improved margins and solid cash flow, while management authorized a new $200M repurchase program.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Flow ⢠Higher Leverage ⢠Rich Valuation PGNY shows solid profitability and strong free cash flow with manageable liquidity, but rising leverage, a richer valuation, and heavy stock compensation temper the outlook.
Price Behavior
Key Price Behavior Insights: ⢠Trend Breakdown ⢠Support Failure ⢠Rebound Risk Support Level: $28.80-$29.00 Resistance Level: $30.70-$31.50 PGNY's trend has weakened over the last month as the July uptrend reversed into a lower-high/lower-low breakdown below $30, leaving $28.80-$29.00 as near-term support and $30.70-$31.50 as resistance.
Sentiment & News
Key News Insights: ⢠Strong Q2 beat ⢠Record profitability ⢠2027 setup Progyny delivered a strong Q2 earnings beat with record revenue and profitability, but the stock remained volatile as investors weighed insider selling, conference news, and a favorable outlook for 2027.
AI Summary
PGNY now looks less like a simple defensive healthcare grower and more like a durability test: strong cash flow and solid margins support the stock, but the key investment question is whether management can sustain growth through the summer slowdown and into the tougher 2027 selling season, because if visibility fades the current valuation and buyback won't prevent multiple compression.
Description
Progyny is a U.S. benefits management company that provides employer-sponsored fertility and family-building programs through tailored plan design, concierge-style member support, and a curated network of reproductive specialists. The company also offers an integrated pharmacy service for treatment medications and administers employer-funded surrogacy and adoption reimbursement programs. Incorporated in 2008 as Auxogyn and renamed Progyny in 2015, it is headquartered in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 20 | Jul 27 | PGNY | Progyny, Inc. | Healthcare momentum candidate with shareholder support: stock rose about 23% over 21 trading days and is near recent highs. Q1 2026 revenue was $328.5M with improved margins and solid cash flow, while management authorized a new $200M repurchase program. | Closed | -0.6% |
| Jul 13 | Jul 20 | PGNY | Progyny, Inc. | Healthcare services momentum candidate: stock gained about 23.7% over 21 trading days and closed at a short-term high, supported by record Q1 2026 revenue of $328.5M, a new $200M buyback, healthy free cash flow, and favorable estimate-revision headlines on 2026-07-09. | Closed | -0.7% |
| Jul 2 | Jul 9 | PGNY | Progyny, Inc. | Favorable momentum plus capital return: stock is up about 19% over 21 trading days at a fresh short-term high, Q1 revenue reached a record $328.5M, free cash flow was $39.6M, leverage is low, and the board approved a new $200M buyback. | Closed | +2.8% |
| May 11 | May 18 | PGNY | Progyny, Inc. | Healthcare services momentum with supportive fundamentals: record Q1 revenue of $328.5M, EPS beat, robust demand commentary, Progyny Select launch, and 8.8M shares repurchased since November. The stock surged about 45% over 21 trading days and 28% over the last five sessions, showing strong near-term follow-through. | Closed | +6.7% |